Paul T Quinlan, General Counsel of Oruka Therapeutics, Inc., sold 14,696 shares of $ORKA on August 14, 2026. The open-market transaction was valued at $1,586,778.56, a per-share price of $107.9735. The Form 4 was filed the same day. After the sale, Quinlan reported holding 54,274 shares.
That sale anchored a larger same-day filing cluster. Quinlan reported five additional open-market sales of $ORKA on August 14: 3,630 shares at $106.0504, 9,193 shares at $110.0039, 10,200 shares at $109.1131, 3,847 shares at $111.1378, and 10,434 shares at $107.1402. Across all six transactions, he sold 52,000 shares for a combined total of about $5.64 million. The 14,696-share block was the largest of the six by share count and dollar value. Per-share prices in the cluster ranged from $106.0504 to $111.1378.
Quinlan's most recent prior $ORKA sale in the database occurred on March 16, 2026. He sold 733 shares at $41.30 each for $30,273. That transaction belonged to a separate multi-insider cluster. Chief Medical Officer Joana Goncalves reported four sales totaling 7,641 shares that day. CEO Lawrence Otto Klein sold 1,729 shares. COO Laura Lee Sandler sold 600 shares. President Arjun Agarwal sold 395 shares. Combined, five $ORKA insiders reported eight open-market sales on March 16, totaling 11,098 shares and about $455,334. The August 14 sales were executed at higher per-share prices than the March 16 cluster.
Other $ORKA insiders also reported open-market sales in 2026. Director Carl Dambkowski sold 105,000 shares across three transactions on May 21, 2026, for a combined $6,191,366 at prices between $58.4267 and $59.9669. President Arjun Agarwal sold 9,699 shares across three transactions on July 13, 2026, for a combined $820,490 at prices between $83.0665 and $84.9012. Quinlan's August 14 cluster was executed at per-share prices between $106.0504 and $111.1378. Oruka Therapeutics is classified in the biotechnology sector and carries a market capitalization of about $7.16 billion in the companies table.
The Form 4 filings for the August 14 sales were dated August 14, 2026, so disclosure occurred the same day as the trades. No $ORKA transactions appeared in the congressional STOCK Act disclosure records. Quinlan's six sales added $5.64 million to the open-market sale volume reported by $ORKA insiders during 2026. The database's $ORKA insider trade history began with sales reported in December 2025 and ran through the August 14, 2026 cluster.